Browse drugs

…Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have rapidly emerged as highly effective pharmacological tools…

…Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) delay gastric emptying and may increase aspiration risk, but t…

…s. There is a rapid, largely hidden surge in direct-to-consumer GLP-1 RA use among patients with IBD. Integrated pathways and prospectiv…

…therapy with SGLT2i and GLP-1 RA relative to those who received SGLT2i monotherapy was significantly lower in patients with HF and T2D…

…particularly relevant for GLP-1 receptor agonists. For example, semaglutide has demonstrated dose-dependent effects on glycemic control and…

…d into: Cohort 1 (CP+GLP-1 RA, n=10,978) with prescriptions for dulaglutide, semaglutide, or tirzepatide; and Cohort 2 (CP without GLP-1 RA…

…ctors associated with obesity in patients with IBD treated with infliximab and vedolizumab across the United Kingdom (UK). Gut 2025;74:A12…

…e study included 25 PWH with metabolic complications prescribed semaglutide at the Modena HIV Metabolic Clinic, Italy, from January 2020 to…

…h new generation agents and longer duration: 3 year exposure to semaglutide or tirzepatide gave an absolute risk difference of −4.71 percen…

…on: Kotecha P, Huang W, Yeh Y-Y, et al., Efficacy and safety of GLP-1 RAs in children and adolescents with obesity or Type 2 diabetes: A …

…omes and 37% of its improvement in CV outcomes were mediated by finerenone’s effect on decreasing UACR.28 While achieving reduction in UAC…